Abstract
The development of metal complexes with anticancer activity has had an enormous impact on cancer chemotherapy. The discovery of cisplatin in the 1960s represented a landmark achievement and ushered in a new era in cancer treatment. Despite the fact that cisplatin has achieved significant clinical benefit for several types of solid tumors, its effectiveness has been hampered by toxic side effects and tumor resistance that often leads to the occurrence of secondary malignancies. However, discovery and use of cisplatin have encouraged investigators to search for and develop novel non platinum-containing metal species with superior anti-cancer activity and low side effects. As examples, gallium salts and gold complexes have been evaluated in phase I and phase II trials. Copper-chelating compounds have also shown promising results in both preclinical and clinical studies. This review provides a comprehensive overview of various non platinum metal complexes and metal-chelating compounds and discusses their potential molecular targets in tumor cells and their applications in cancer therapy.
Keywords: Metal complexes, copper-binding compounds, gold complexes, gallium, proteasome inhibitors, anticancer drugs, apoptosis
Current Pharmaceutical Design
Title: Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Volume: 15 Issue: 7
Author(s): Di Chen, Vesna Milacic, Michael Frezza and Q. Ping Dou
Affiliation:
Keywords: Metal complexes, copper-binding compounds, gold complexes, gallium, proteasome inhibitors, anticancer drugs, apoptosis
Abstract: The development of metal complexes with anticancer activity has had an enormous impact on cancer chemotherapy. The discovery of cisplatin in the 1960s represented a landmark achievement and ushered in a new era in cancer treatment. Despite the fact that cisplatin has achieved significant clinical benefit for several types of solid tumors, its effectiveness has been hampered by toxic side effects and tumor resistance that often leads to the occurrence of secondary malignancies. However, discovery and use of cisplatin have encouraged investigators to search for and develop novel non platinum-containing metal species with superior anti-cancer activity and low side effects. As examples, gallium salts and gold complexes have been evaluated in phase I and phase II trials. Copper-chelating compounds have also shown promising results in both preclinical and clinical studies. This review provides a comprehensive overview of various non platinum metal complexes and metal-chelating compounds and discusses their potential molecular targets in tumor cells and their applications in cancer therapy.
Export Options
About this article
Cite this article as:
Chen Di, Milacic Vesna, Frezza Michael and Dou Ping Q., Metal Complexes, their Cellular Targets and Potential for Cancer Therapy, Current Pharmaceutical Design 2009; 15 (7) . https://dx.doi.org/10.2174/138161209787582183
DOI https://dx.doi.org/10.2174/138161209787582183 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functions of Third Extracellular Loop and Helix 8 of Family B GPCRs Complexed with RAMPs and Characteristics of their Receptor Trafficking
Current Protein & Peptide Science Barker and Brenner: A Basis for Hypertension?
Current Hypertension Reviews ENaC Modulators and Renal Disease
Current Molecular Pharmacology Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus
Current Drug Targets The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Stereospecific Synthesis of m-Hydroxymexiletine Enantiomers
Drug Metabolism Letters Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology How Could We Reduce Antibiotic Use in Critically Ill Patients?
Infectious Disorders - Drug Targets In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?
Medicinal Chemistry NO-NSAIDs: From Inflammatory Mediators to Clinical Readouts
Inflammation & Allergy - Drug Targets (Discontinued) Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Binary Actin-ADP-Ribosylating Toxins and their Use as Molecular Trojan Horses for Drug Delivery into Eukaryotic Cells
Current Medicinal Chemistry Amniotic Fluid Embolism: What Level of Scientific Evidence can be Drawn? A Systematic Review
Current Pharmaceutical Biotechnology